[go: up one dir, main page]

WO2009116764A3 - Cell migration, cell infiltration, or neovascularization inhibitor through degradation of function of ptk7 protein - Google Patents

Cell migration, cell infiltration, or neovascularization inhibitor through degradation of function of ptk7 protein Download PDF

Info

Publication number
WO2009116764A3
WO2009116764A3 PCT/KR2009/001298 KR2009001298W WO2009116764A3 WO 2009116764 A3 WO2009116764 A3 WO 2009116764A3 KR 2009001298 W KR2009001298 W KR 2009001298W WO 2009116764 A3 WO2009116764 A3 WO 2009116764A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell
degradation
function
inhibitor
cell migration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2009/001298
Other languages
French (fr)
Korean (ko)
Other versions
WO2009116764A2 (en
Inventor
이승택
권영근
신원식
맹용선
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Industry Academic Cooperation Foundation of Yonsei University
Original Assignee
Industry Academic Cooperation Foundation of Yonsei University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020090021595A external-priority patent/KR101123130B1/en
Application filed by Industry Academic Cooperation Foundation of Yonsei University filed Critical Industry Academic Cooperation Foundation of Yonsei University
Priority to JP2010503992A priority Critical patent/JP2010522775A/en
Priority to CN200980000012A priority patent/CN101678075A/en
Publication of WO2009116764A2 publication Critical patent/WO2009116764A2/en
Publication of WO2009116764A3 publication Critical patent/WO2009116764A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a cell migration, cell infiltration, or neovascularization inhibitor through the degradation of a function of the PTK7 protein. The inhibitor of the present invention inhibits neovascularization, cell migration, cell infiltration, and cell adhesion caused by VEGF, and inhibits activation of PI3-kinase and Akt. Further, the inhibitor of the present invention inhibits the activation of FAK and paxilline, thus effectively inhibiting neovascularization, cell migration, and cell infiltration in a living body.
PCT/KR2009/001298 2008-03-17 2009-03-16 Cell migration, cell infiltration, or neovascularization inhibitor through degradation of function of ptk7 protein Ceased WO2009116764A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2010503992A JP2010522775A (en) 2008-03-17 2009-03-16 Inhibitor of cell migration, invasion or angiogenesis through functional inhibition of PTK7 protein
CN200980000012A CN101678075A (en) 2008-03-17 2009-03-16 Cell migration, cell infiltration, or neovascularization inhibitor through degradation of function of ptk7 protein

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2008-0024599 2008-03-17
KR20080024599 2008-03-17
KR1020090021595A KR101123130B1 (en) 2008-03-17 2009-03-13 Inhibitors of cell migration, invasion, or angiogenesis by blocking the function of PTK7 protein
KR10-2009-0021595 2009-03-13

Publications (2)

Publication Number Publication Date
WO2009116764A2 WO2009116764A2 (en) 2009-09-24
WO2009116764A3 true WO2009116764A3 (en) 2009-11-26

Family

ID=41091371

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/001298 Ceased WO2009116764A2 (en) 2008-03-17 2009-03-16 Cell migration, cell infiltration, or neovascularization inhibitor through degradation of function of ptk7 protein

Country Status (1)

Country Link
WO (1) WO2009116764A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2380909A1 (en) * 2010-04-26 2011-10-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PTK-7 protein involved in breast cancer
BR112016025291A2 (en) 2014-04-30 2017-12-26 Abbvie Stemcentrx Llc anti-ptk7-drug antibody conjugates

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007067730A2 (en) * 2005-12-08 2007-06-14 Medarex, Inc. Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007067730A2 (en) * 2005-12-08 2007-06-14 Medarex, Inc. Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Korean Society for Biochemistry and Molecular Biology, Spring Conference", 2005, article SHIN, W. S. ET AL.: "Extracellular domain of PTK7 inhibits the VEGF-induced migration, invasion and tube formation of HUVECs", pages: 293 *
"Korean Society for Biochemistry and Molecular Biology, Spring Conference", 2007, article SHIN, W. S. ET AL.: "The extracellular domain of PTK7 prevents the VEGF-induced movement of HUVECs through reducing actin polymerization", pages: 319 *

Also Published As

Publication number Publication date
WO2009116764A2 (en) 2009-09-24

Similar Documents

Publication Publication Date Title
WO2009158033A3 (en) Antagonists of activin-actriia and uses for increasing red blood cell levels
WO2010062396A3 (en) Virus like particle compositions and methods of use
WO2010136492A3 (en) Combination of a tnf-alpha antagonist and a vegf antagonist for use in the treatment or prevention of diseases of the eye.
EP4279512A3 (en) Cytotoxicity-inducing therapeutic agent
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2010045388A3 (en) Use of mmp-9 and mmp-12 binding proteins for the treatment and prevention of systemic sclerosis
WO2011037978A8 (en) Guidewire-style pacing lead
WO2007143674A3 (en) Methods for buccal, lingual or sublingual dosing regimens of epinephrine for the treatment of allergic emergencies
WO2010085100A3 (en) Novel cellular transmembrane domain and intracellular transduction system containing the same
WO2009100255A3 (en) Modified leptin polypeptides and their uses
EP2246402A4 (en) Resin composition, laminate using the same, and molded body using the laminate
WO2010132370A8 (en) Soluble trem-1 family peptides and methods of use
WO2009142738A3 (en) Compositions and methods for diagnosing and treating cancer
WO2009105585A3 (en) Postsynaptically targeted chemodenervation agents and their methods of use
IL213748A (en) Cell adhesion inhibiting peptides, compositions comprising the same and uses thereof
MX2009004186A (en) 2-phenyl-6-aminocarbonyl-pyrimidine derivatives.
WO2009156182A3 (en) Uracil derivatives and use thereof
WO2009068708A3 (en) Pharmaceutical composition with prolonged release of somatostatin or an analogue thereof
WO2009103959A3 (en) Histidine and/or histidine derivative for the treatment of inflammatory skin diseases
WO2008154132A3 (en) Implantable medical devices with elastomeric block copolymer coatings
ZA201000581B (en) 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives,preparation and therapeutic use thereof
WO2009156071A8 (en) Combination of amidine derivates with cyclic depsipeptides
WO2009116764A3 (en) Cell migration, cell infiltration, or neovascularization inhibitor through degradation of function of ptk7 protein
WO2009123486A8 (en) Use of compounds in the treatment of tau-induced cytotoxicities
WO2008091643A3 (en) Evaluating synergy of combinations comprising an antibody in immune suppressive pathways concurrent to immunotherapy

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980000012.1

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2010503992

Country of ref document: JP

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09722326

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09722326

Country of ref document: EP

Kind code of ref document: A2